Alternative splicing in Alzheimer's disease: event-level evidence, risk-locus biology, and RNA-based therapeutic perspectives. (PubMed, Gene) - Sep 16, 2026 - "ApoER2 exon 19 correction provides AD-specific preclinical evidence for splice-event modulation, whereas BIIB080/MAPTRx illustrates the feasibility of CNS antisense oligonucleotide delivery and target-engagement monitoring in patients...Overall, AS should not be viewed as a single pathogenic mechanism in AD. Selected splice events may improve AD risk-locus interpretation, molecular stratification, biomarker development, and the design of RNA-based therapeutic strategies."
Journal • Review • Alzheimer's Disease • CNS Disorders • APOE • CD33 • MAPT • TARDBP
|
|
Daoyuan Yue; Jinglin Li; Wenge Xie; Xiong Wang; Zhigang Xiong
|